• Novel agent reactivates an immune call by LIF blockade firstwordpharma
    June 12, 2019
    Results from a study spearhead by researchers at the Vall d´Hebron Institute of Oncology (VHIO), show that the blockade of the multi-functional cytokine LIF induces tumor-infiltrating T Cells to hone in on and eliminate cancer.
PharmaSources Customer Service